Heart Problems Hit Hopes for Experimental Amgen, UCB Bone Drug Heart Problems Hit Hopes for Experimental Amgen, UCB Bone Drug

Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news